Study guide

2.3 Bayesian Risk Calculations

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

2.3 Bayesian Risk Calculations

Key Takeaways Explain This Topic AI

Bayesian carrier analysis combines a Mendelian or population prior with conditional probabilities of the observed data under carrier vs non-carrier hypotheses

Joint probability = prior × conditional; posterior odds = joint(carrier):joint(non-carrier); posterior probability = joint(carrier)/sum of joints

Negative information (unaffected status at a penetrant age, negative biochemical test, negative molecular screen with known detection rate) lowers posterior carrier risk but rarely to zero

Worked XL and AR examples require writing prior, conditional, joint, and posterior rows explicitly so arithmetic errors are visible

Detection rate and penetrance must match the test and age used in the stem; using 100% detection when the stem gives 95% is a classic trap

Last updated: August 2026

2.3 Bayesian Risk Calculations

Quick Answer: Build a two-hypothesis table ( carrier vs not ): list prior , multiply by conditional probability of the data under each hypothesis to get joint probabilities, then normalize joints to posterior probabilities. Negative tests reduce—but do not eliminate—carrier risk when detection rate < 100%.

Domain 2A Bayesian items reward orderly tables more than mental shortcuts. If your posterior does not sit between 0 and the prior after negative evidence, restart the arithmetic.

Why Bayes Appears on the CGC Exam

Real counseling almost never stops at 1/2 or 2/3. Clients bring negative panels, normal CK values, multiple healthy sons, or ethnicity-specific screens with published detection rates. Bayesian analysis is how you turn those facts into a residual carrier probability.

The Four-Column Habit

For hypothesis H1 = carrier and H2 = not carrier:

  • Step Meaning Formula habit
  • Prior Probability before new data Mendelian position or population frequency
  • Conditional P(data | hypothesis) Detection rate, penetrance, segregation of relatives' phenotypes
  • Joint Prior × conditional Multiply across each row
  • Posterior Normalized joint Joint / (joint1 + joint2)

Posterior odds = joint(H1):joint(H2). Posterior probability carrier = joint(H1)/(joint1+joint2).

Worked Example A — X-Linked Carrier Risk with Negative Information

Stem (teaching numbers): A woman has one brother with Duchenne muscular dystrophy (DMD). Assume for this item that her mother is an obligate carrier (for example, the stem also notes an affected maternal uncle), so the woman's prior carrier risk = 1/2 . She has two unaffected sons and no molecular testing yet. Approximate the probability an affected son would have been recognized as nearly 1 if she were a carrier (teaching simplification: each son of a carrier has 1/2 chance of being affected, so probability both sons unaffected given she is a carrier = (1/2)×(1/2) = 1/4 ). Probability both sons unaffected if she is not a carrier ≈ 1.

  • Hypothesis Prior Conditional (2 unaffected sons) Joint Posterior
  • Carrier 1/2 1/4 (1/2)×(1/4)=1/8 (1/8)/(1/8+1/2)= (1/8)/(5/8)=1/5
  • Not carrier 1/2 1 (1/2)×1=1/2 (1/2)/(5/8)=4/5

Arithmetic check: Joints 1/8 + 4/8 = 5/8. Posterior carrier risk = 1/5 (20%) , down from 50%.

If the stem instead gives a CK-based conditional (for example, normal CK detects 2/3 of adult carriers—illustrative), replace the conditional column with P(normal CK | carrier) and P(normal CK | not carrier)≈1, then renormalize. Never mix CK and molecular conditionals unless the stem stacks independent tests carefully.

Variant: Isolated Case and Maternal Prior < 1

If the affected male is an isolated case, the mother's carrier prior may be less than 1 because of de novo variants in the son or maternal mosaicism. Exam stems usually supply the prior to use (for example, 2/3). Use the given prior; do not invent a different empiric number unless provided.

Worked Example B — Autosomal Recessive Carrier Screening with Detection Rate

Stem (teaching numbers): An Ashkenazi Jewish consultand has a population prior carrier risk of 1/25 for a condition. She has a negative targeted carrier screen with detection rate 95% (sensitivity 0.95 for carriers). Specificity ≈ 1 for this teaching item (true non-carriers almost never screen positive).

Conditionals for a negative result:

  • P(neg | carrier) = 1 − 0.95 = 0.05
  • P(neg | not carrier) ≈ 1

Priors:

  • P(carrier) = 1/25
  • P(not) = 24/25
  • Hypothesis Prior Conditional (negative screen) Joint Posterior
  • Carrier 1/25 0.05 0.002 0.002 / (0.002 + 0.96) ≈ 0.002078
  • Not carrier 24/25 1 0.96 ≈ 0.9979

Posterior carrier risk ≈ 0.00208 ≈ 1/481 (about 1/480).

Counseling translation: Her residual carrier risk after a negative 95% detection screen is roughly 1/480 , not zero. Partner testing and residual-risk couple calculations (Section 2.5) still matter for some indications.

Same Math with Fractions Only

Joint carrier = (1/25)×(1/20) if you express 0.05 as 1/20 → 1/500 . Joint not = 24/25 . Posterior = (1/500) / (1/500 + 24/25) = (1/500) / (1/500 + 480/500) = 1/481 . Same result.

Worked Example C — Combining Mendelian 2/3 with a Negative Screen

Unaffected sib of an AR proband: prior carrier = 2/3 . Negative screen detection rate 90% .

  • Hypothesis Prior Cond. (neg) Joint Posterior
  • Carrier 2/3 0.10 0.0667 0.0667/(0.0667+0.3333) ≈ 0.167
  • Not carrier 1/3 1 0.3333 ≈ 0.833

Posterior ≈ 1/6 . The 2/3 prior falls substantially but remains clinically meaningful if the partner is a carrier or untested.

Stacking Independent Conditionals

If two independent negative tests apply, multiply conditionals under the carrier row: P(data | carrier) = P(test1 neg | carrier) × P(test2 neg | carrier). Only multiply when independence is reasonable (exam stems usually imply this). Dependent tests (overlapping variant coverage) should not be multiplied as if independent.

  • Exam Traps in Bayesian Items
  • Forgetting to normalize joints (reporting the joint as if it were the posterior)
  • Using P(pos | carrier) when the person tested negative
  • Setting residual risk to 0 after any negative screen
  • Using 1/2 for an unaffected AR sib prior instead of 2/3 before Bayes
  • Ignoring that unaffected sons modify XL carrier risk only under the carrier hypothesis
  • Mixing population prior with Mendelian prior incorrectly (choose the prior that matches pedigree information)
  • Communication After the Math

Present posteriors as absolute risks and, when helpful, as reductions from the prior ("from 50% to about 20% after two unaffected sons"). Pair the number with the next medical action: partner testing, expanded sequencing, prenatal options, or reassurance with caveats. Bayesian output without a follow-up plan is incomplete counseling—and incomplete Domain 2A performance.